Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 26 01:05PM ET
7.75
Dollar change
-0.11
Percentage change
-1.40
%
IndexRUT P/E- EPS (ttm)-2.48 Insider Own19.50% Shs Outstand110.46M Perf Week1.44%
Market Cap856.08M Forward P/E- EPS next Y-2.31 Insider Trans0.00% Shs Float88.93M Perf Month-15.67%
Income-242.30M PEG- EPS next Q-0.59 Inst Own91.35% Short Float8.21% Perf Quarter-28.90%
Sales0.00M P/S- EPS this Y-0.41% Inst Trans6.76% Short Ratio5.27 Perf Half Y-8.18%
Book/sh1.85 P/B4.20 EPS next Y4.93% ROA-65.53% Short Interest7.30M Perf Year35.25%
Cash/sh3.04 P/C2.55 EPS next 5Y- ROE-78.47% 52W Range4.28 - 12.61 Perf YTD31.80%
Dividend Est.- P/FCF- EPS past 5Y15.33% ROI-73.21% 52W High-38.54% Beta1.74
Dividend TTM- Quick Ratio6.44 Sales past 5Y-6.78% Gross Margin- 52W Low81.07% ATR (14)0.58
Dividend Ex-Date- Current Ratio6.44 EPS Y/Y TTM-5.88% Oper. Margin- RSI (14)32.18 Volatility7.30% 7.20%
Employees164 Debt/Eq0.06 Sales Y/Y TTM- Profit Margin- Recom1.55 Target Price16.80
Option/ShortYes / Yes LT Debt/Eq0.05 EPS Q/Q0.23% Payout- Rel Volume0.37 Prev Close7.86
Sales Surprise- EPS Surprise-13.03% Sales Q/Q- EarningsNov 12 BMO Avg Volume1.38M Price7.75
SMA20-10.34% SMA50-21.50% SMA200-13.59% Trades Volume293,106 Change-1.40%
Date Action Analyst Rating Change Price Target Change
Dec-11-24Downgrade Needham Buy → Hold
Feb-26-24Downgrade Robert W. Baird Outperform → Neutral $14 → $8
Feb-08-24Initiated Citigroup Buy $11
Dec-11-23Downgrade Wedbush Outperform → Neutral $5
Dec-08-23Initiated JP Morgan Overweight $18
Apr-28-23Initiated Robert W. Baird Outperform $20
Mar-27-23Resumed H.C. Wainwright Buy $28
Dec-14-22Initiated Needham Buy $24
Jun-28-22Initiated Guggenheim Buy $15
Oct-11-21Initiated H.C. Wainwright Buy $25
Dec-09-24 07:00AM
Dec-08-24 12:00PM
Nov-05-24 09:00AM
Oct-23-24 07:00AM
Oct-09-24 08:03AM
08:00AM Loading…
Sep-03-24 08:00AM
Sep-02-24 05:22PM
Aug-06-24 08:00AM
Jun-28-24 09:18AM
Jun-27-24 08:00AM
Jun-14-24 07:30AM
May-23-24 05:05PM
05:01PM
May-07-24 01:52PM
08:00AM
09:00AM Loading…
Apr-09-24 09:00AM
Mar-13-24 07:06AM
Feb-28-24 04:32AM
Feb-26-24 08:00AM
Feb-22-24 02:30PM
Feb-14-24 07:00AM
Feb-05-24 09:00AM
Jan-09-24 08:00AM
Jan-02-24 08:00AM
Dec-11-23 07:55AM
Dec-09-23 01:30PM
Dec-07-23 09:00AM
Dec-04-23 08:00AM
Nov-29-23 08:00AM
Nov-02-23 09:00AM
12:30PM Loading…
Oct-14-23 12:30PM
Aug-13-23 08:51AM
Aug-08-23 08:00AM
Jul-10-23 07:35PM
Jun-09-23 04:01PM
Jun-07-23 09:00AM
Jun-06-23 08:25PM
04:05PM
Jun-03-23 02:15PM
May-23-23 08:00AM
May-09-23 08:00AM
Apr-17-23 09:00AM
Apr-12-23 08:00AM
Mar-14-23 08:00AM
Feb-01-23 08:00AM
Jan-11-23 11:03AM
Jan-09-23 08:00AM
Jan-05-23 08:00AM
Dec-11-22 05:30PM
Dec-05-22 08:00AM
Nov-28-22 04:15PM
Nov-14-22 07:00AM
Nov-09-22 08:00AM
Nov-03-22 09:05AM
Oct-26-22 07:00AM
Aug-14-22 12:21PM
Aug-09-22 07:00AM
Aug-04-22 11:22AM
Jun-20-22 11:09AM
Jun-16-22 04:01PM
Jun-13-22 09:48PM
06:00AM
Jun-10-22 07:00AM
Jun-06-22 10:15AM
Jun-02-22 08:00AM
May-12-22 10:00AM
May-10-22 07:00AM
May-06-22 08:00AM
Apr-11-22 07:00AM
Mar-29-22 07:00AM
Mar-15-22 07:00AM
Mar-08-22 05:10PM
Feb-01-22 05:29AM
Jan-05-22 07:00AM
Nov-22-21 07:00AM
Nov-10-21 07:00AM
Nov-02-21 07:00AM
Oct-29-21 09:46AM
Oct-12-21 07:59PM
Oct-07-21 09:00AM
Oct-01-21 07:00AM
Aug-16-21 07:00AM
Jul-27-21 07:00AM
Jul-13-21 11:11AM
Jun-29-21 07:00AM
Jun-15-21 11:37AM
May-26-21 07:00AM
May-12-21 07:00AM
May-03-21 07:00AM
Apr-06-21 07:00AM
Mar-17-21 02:27AM
Mar-16-21 07:00AM
Feb-22-21 07:00AM
Feb-18-21 07:00AM
Feb-11-21 07:00AM
Dec-04-20 05:16PM
Dec-01-20 11:08PM
Nov-30-20 04:01PM
07:00AM
Nov-20-20 07:00AM
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.